Thec linical importanceo fa symptomaticp roximal and distal deep vein thrombosis (DVT) remains uncertain and controversial.The aimofthis retrospective,post-hoc analysiswas to examinemortality and risk factors fordevelopment of proximalDVT in hospitalizedpatientswith acute medicalillness who were recruitedinto arandomized,prospectiveclinical trial of thromboprophylaxis with dalteparin (PREVENT).We analyzed 1738 patients who had not sustainedas ymptomatic venous thromboembolic eventbyDay 21 and who had acompletecompression ultrasound of the proximaland distalleg veins on Day21. We examined the 90-day mortalityratesinpatientswith asymptomatic proximalD VT (Group I, N=8 0), asymptomaticd istal DVT(GroupII, N=118) or no DVT(GroupIII, N=1540).The 90-daym ortality ratesw ere1 3.75%,3 .39%, and 1.92% for
Introduction
Ve nous thromboembolism (VTE),comprising deepveinthrombosis (DVT) and pulmonaryembolism(PE), is oftenundetected and asymptomatic in hospitalized patients. Prophylaxis maybe the most effectivemeans of reducing the morbidity and mortality associatedwith this condition (1, 2) .
ProximalD VT is more commonlya ssociatedw ith PE than distal DVT (3) (4) (5) (6) (7) (8) (9) , butthe relative risk of deathassociatedwith asymptomatic proximalv ersus distal DVTc ontinues to be a source of controversya nd uncertainty. The recentlyc ompleted Prospective E valuation of DalteparinEfficacyfor Prevention of V T E in Immobilized Patien tsT rial (PREVENT) investigated the efficacyand safety of alow-molecular-weight heparin,dalteparin, for the prevention of VTEingroups of acutelyill hospitalized patients with risk factorsf or VTE. The objectiveso ft his post hoc retrospective analysis of PREVENT data were: 1) to comparethe mortality rates in patients with asymptomatic proximal DVT, asymptomatic distalDVT,ornoDVT,and 2) to identify risk factorsfor development of proximalD VT.
Materials andmethods
We conducted aretrospective, post-hocanalysis of patients enrolled in the PREVENTs tudy.P REVENTw as ar andomized, double-blind,p lacebo-controlled, multicenter,m ultinational trial of once-dailydalteparin(5000 IU subcutaneous) or placebo for 14 days, with afollow-up period of 90 days, for the prevention of VTE in acutelyill hospitalized patients. Themethods have beendescribed in detail previously (10, 11) .
Patients were at least40years of age with an acutemedical condition requiring aprojected hospitalization for 4ormore days and had had no more than 3daysofprior immobilization. The major diagnostic subgroups in PREVENTi ncludeda cutec ongestive heart failure(NewYork HeartAssociation [NYHA] class III or IV), acuterespiratoryfailurethat did not require ventilatorys upporto ro thera cutem edical conditions.P atients in the lattergrouphad to have at leastone of the following additional risk factors: age ≥ 75 years,cancer,previousDVT or PE,obesity (body mass index ≥ 30 kg/m 2 for mena nd ≥ 28.6 kg/m 2 for women),v aricosev eins and/or chronic venous insufficiency, hormone replacement therapy, historyo fc hronic heart failure, chronic respiratoryfailure, or myeloproliferativesyndrome.
The primarye ndpoint of PREVENTw as the composite of objectivelyverified symptomatic DVT, PE,asymptomatic proximalD VT,a nd sudden death by Day2 1. Symptomatic VTE requiredimaging confirmation (e.g., compression ultrasound or venographyfor DVT, lung scans or angiographyfor PE). Patients whodid not have confirmed symptomatic VTEbyDay 21 underwent compression ultrasound examination of the lowerextremity.The compression ultrasound wasperformed in both legs on a centimeter-by-centimeterbasis, wasrecorded on videotape,and forwarded to acore reading lab for blindedevaluation. Theprincipal criterionfor diagnosis of DVTwas failureofaveintocompress completely upon the application of pressure.I fb oth a proximal and distal DVTw ere identified, the patient wasa ssignedtothe proximal-DVT group.
The present reportincludespatients for whom atechnically adequate(i.e., includingproximaland distal veins) Day-21 compression ultrasound wasavailableand for whom the vital status at Day90was known.
The management of patients with DVT, eitherp roximalo r distal, wasleft to the discretion of the treating physicians and was not dictatedbythe protocol. Data on patient management following the diagnosis of DVTwere notcollected.
Correlations were calculatedusing univariate and multivariatemodels (stepwise logistic regression analyses). Formultivariateanalysis, death wasthe dependent variable and the independent variablesincludedbaseline demographic and clinical characteristics (including allofthe qualifying diagnostic categories), and the presenceofproximalordistalD VT.
Results
Atotal of 3706 patients were enrolledat219 centersin26coun-tries (11) .The incidenceofthe primarycomposite endpoint was 2.77% in the dalteparin group and 4.96% in the placebo group, a risk reduction of 45%(relativerisk 0.55; 95% CI 0.38-0.80; p =0.0015).
Of patients alive on Day21who had not sustained asymptomatic, verified event,1738 had an adequate compression ultrasound of both the proximal and distal veins and constitute the Among patients with proximal DVT, 2patients receiving dalteparin died (7.4%)and 9patients in the placebo group died (17%).
The survivalcurvesfor the threegroups are illustrated in Figure 1 . The curvesseparateearlyand the difference in cumulative mortality progresses throughthe observation period.The adjudicated causes of death betweenDay 21 and Day90are summarized in Table2.Inmultivariate analysis, onlytwo variableswere associatedwith asignificantly increased risk of death: asymptomatic proximalDVT (p <0.0001) and age >75(p=0.0051). The individual clinicalv ariablest hat were significantly associated withthe development of proximalD VT included age ≥ 75 (p = 0.0005), prior DVT(p=0.001), and varicoseveins (p =0.04).
Discussion
We have demonstrated that, in an acutelyill, immobilized medical population, the presence of compression ultrasound-identified asymptomatic proximalD VT wasa ssociatedw ith ah igh 90-daymortality.Nopreviousstudy haslinked the presence of asymptomatic proximalDVT to mortality.The Group Imortality rate of 13.8% wasc omparable to the12.5% mortality rate observedinhigh risk patients with symptomatic proximalD VT in thePREPICstudy (12) and the 17.4% 90-daymortality rate previouslyr eported in al arge study of patients with PE (13) .I n contrasti nt he present study,t he observedi ncrease in 90-day mortality in the presence of asymptomatic distalD VT didn ot reachstatistical significance.
Thea ssociation between asymptomatic proximalD VT and 90-day mortality persisted in univariate and multivariate analyses. Therefore,though therewere differences in baseline characteristics amongthe threegroups of patients (e.g.inthe prevalenceofunderlying diagnoses),these did not account for the difference in 90-daym ortality.H owever,o theru nidentified baseline characteristics could confoundthe results.
The finding that asymptomatic proximal DVTisassociated withah igh mortality rate supports the use of asymptomatic proximalD VT as an appropriatee ndpoint in clinicalt rials of thromboprophylaxis. Furthermore,t his emphasizest he critical importanceofprevention of VTE because it is not routine practice to conductsurveillanceimaging in asymptomatic patients.
Thougho ur study did not demonstrate as ignificant difference in mortality between GroupsIIand III, this cannot be construed as proof that distal DVTs arebenign.Therewas anumericalincrease in mortality among patients with distal DVTs comparedwith patients without DVT. It would require asubstantially larger sample size to adequately addresswhetherornot this represents asignificant increase in mortality. We also identified advanced age, prior history of VTE, and varicoseveins as the most potent predictorsofpatients whodevelop proximalD VT.
There areseveral limitations to the present study.Compression ultrasound is more accurate for the diagnosis of proximal DVTthan it is for diagnosing distal DVT (14) . Thus, our observations with respect to distalD VTs are lesscertain thanour observations with respect to proximalDVTs. However, we included in the present analysis onlythose patients whohad had atechnically adequatec ompression ultrasound of both proximal and distal veins, and we ensured the uniformity of ultrasonographic criteriabyusing acore lab.
The association betweenproximalDVT and subsequent mortality doesnot necessarilyestablish causality.Although ablinded endpoints committeeadjudicatedthe causes of death, we cannot be certain of the precise contribution of VTEt ot he observed fatalities. DVTo rP Ea sac ausativeo rc ontributing factor to deaths in this population with significant cardiacorpulmonary disease wasnot systematicallyevaluated. Withoutautopsy data, it would be nearlyimpossible to ascertain the precise frequency of PE. Furthermore,t he association of proximal DVTa nd increased mortality could reasonablyb ei nterpreted in several ways. Plausible explanations include that the proximal DVT'sdirectlycontributed to increased mortality via their propensityto embolizeor, alternatively, thatdeveloping aDVT is amarker for severe underlying illness.
Asymptomatic proximalDVT is often used as an endpointin clinical trials of VTEprophylaxis. Ourstudy demonstrated the clinical importanceofasymptomatic proximalDVT as amarker of high mortality risk and thus providesevidencesupporting the use of asymptomatic proximal DVTasanendpoint in preventive studies.
